Generali Asset Management SPA SGR Invests $3.26 Million in Insulet Co. (NASDAQ:PODD)

Generali Asset Management SPA SGR bought a new stake in Insulet Co. (NASDAQ:PODD) during the 4th quarter, Holdings Channel.com reports. The firm bought 12,501 shares of the medical instruments supplier’s stock, valued at approximately $3,264,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at $36,000. SRS Capital Advisors Inc. boosted its position in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 56 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial acquired a new stake in Insulet during the 4th quarter worth about $57,000. Finally, Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 246 shares during the period.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.47% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PODD. Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Wells Fargo & Company raised their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Raymond James reiterated an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Piper Sandler raised their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Citigroup upped their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Price Performance

Shares of NASDAQ PODD opened at $265.82 on Thursday. The company has a market capitalization of $18.67 billion, a PE ratio of 45.91, a PEG ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock’s 50 day moving average price is $272.21 and its 200-day moving average price is $256.19. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. On average, equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.